Naloxegel (Moventig®)

Assessment Status Rapid Review Complete
Drug Naloxegel
Brand Moventig®
Indication Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Assessment Process
Rapid review commissioned 10/02/2015
Rapid review completed 13/04/2015
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended

Naloxegel (Moventiq®) is to be reimbursed under the Community Drugs Schemes subject to conditions.